Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Inclusion Criteria: * Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy * Female or male aged 18 years and older at the time of enrollment. * Not pregnant and not nursing. * No active infection requiring parenteral antibiotic(s). * Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib * No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients). * Patients who are able to understand and willing to s…
Minocycline 100mg PO twice daily (or doxycycline alternative)
Face: Hypochlorous acid solution applied every morning
Face: Hydrocortisone 2.5% cream (or equivalent) applied twice daily
Trunk: Triamcinolone 0.1% cream (or equivalent) applied twice daily
Scalp: Clobetasol propionate 0.05% solution (or equivalent) applied twice daily
Broad-spectrum sunscreen (SPF 30 or higher) applied daily to sun- exposed areas
Ivermectin 200mcg/kg orally weekly PLUS